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Introduction
Recently, there is an increase in the number of individuals 
diagnosed with diabetes- A medical disorder associated with 
an imbalance in glucose homeostasis. Many factors contribute 
to this condition and one of the most important factors, in 
addition to diet, is a lack of Physical Activity (PA)/ Exercise 
(EX) and adoption of partial or complete sedentary lifestyle. 
PA is the daily activities an individual performs in addition 
to planned EX regimens. Interventions that include increased 
physical activity/ exercise along with medications are highly 
recommended. However, with several different options available 
for EX regimens, it is important to select the most beneficial 
form of EX for individuals, considering the existing lifestyle and 
co-morbidities. This review focuses on the various factors and 
mechanisms that are affected by diabetes and physical activity. 
PubMed and Medline were the databases used to collect relevant 
literature, and they are compiled and discussed. In addition, the 
risks and barriers associated with the different types of PA are 
also discussed.
Diabetes
Diabetes is a medical condition that affects 347 million people 
around the world. In 2014, the global prevalence of diabetes was 
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estimated to be 9% among adults aged 18 and above [1]. In the 
United States, in 2012, 29.1 million people (9.3% of the population) 
had diabetes [2] and diabetes remained the 7th leading cause of 
death in the US, in 2010. The total cost of diagnosed diabetes is 
$245 billion in 2012. This included $176 billion in direct medical 
expenses for emergency care, hospitalization, office visits and 
medications and $69 billion as indirect costs such as days absent 
from work, reduced productivity, unemployment due to diabetes-
related disability and lost productivity due to early mortality [3].
There are two major types of chronic diabetic conditions 
identified – Type I Diabetes Mellitus (T1DM) and Type II Diabetes 
Mellitus (T2DM). A temporary diabetic condition is also seen 
during pregnancy in some women and is termed gestational 
diabetes mellitus. Diabetes, in general, is characterized by 
increased circulating blood sugar and uncontrolled diabetes. 
These adverse effects lead to many complications that affect 
several organs like skin, eye, kidney, heart, nerves, bone, etc. 
resulting in ketoacidosis, high blood pressure, stroke and 
severe Diabetic Neuropathy (DPN) of the extremities [4-7]. 
DPN affects predominantly the distal segments of the lower 
limbs impairing walking and daily activities [4,7]. In addition, 
diabetic patients have decreased skin thickness, increased skin 
hardness, thickened tendons, muscle atrophy, impairment and 
activation delays, and decreased bone mineral density, limited 
mobility at joints, less thick fat pad and gait changes [8-14]. The 
severity of the complications advances with age and adds to the 
complications of the normal aging process.
Muscle strength of the upper and lower body correlated with 
measures of diabetic complications especially with sensory and 
autonomic functions [6]. Loss of muscle strength is associated 
with atrophy of ankle and foot muscles due to denervation caused 
by loss of motor axons combined with insufficient innervations 
[15]. Also, Peripheral Arterial Disease (PAD), due to diabetes, 
may aggravate muscle weakness and atrophy of limbs including 
the upper limbs [16] where handgrip strength decreased with 
age [8].
T1DM is usually diagnosed in children and is characterized by 
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a lack of insulin due to non-functional or destroyed pancreatic β 
cells. The auto-destruction of β cells [17] is controlled genetically. 
In addition, T1DM patients have greater utilization of fatty acid 
and oxidation as well as, decreased glucose utilization [18]. The 
kidneys are overworked in T1DM patients, as these patients 
have higher hyperfiltration rate due to increasing glomerular 
hypertension in the kidneys [19] and undergo diabetic 
nephropathy [20]. However, only 5% of all the individuals 
diagnosed with diabetes are diagnosed with T1DM, which is 
about 1.25 millions of Americans [21].
T2DM, on the other hand, is seen in adults and older 
individuals. These patients usually develop insulin resistance 
(IR) as underutilization of insulin leads to increased circulation 
in the blood resulting in decreased production of insulin, and 
eventual failure of β cells [2]. A Majority of the total number of 
patients diagnosed with diabetes 90-95% is T2DM [2]. 
Actually, IR starts before β cell damage and shut down of 
the pancreas [22-27]. For insulin-dependent glucose transport, 
insulin first binds to the insulin receptor on the plasma 
membrane and triggers the signaling pathway to mobilize 
glucose from the cells. After insulin binds to its receptor, Insulin 
Receptor Substrate-I (IRS-I) is phosphorylated and this activates 
Phosphoinositide-3 Kinase (PI3K) and protein kinase B (Akt), 
leading to translocation of glucose transporter 4 (GLUT4) to 
the membrane and subsequent transportation of glucose into 
the cells. In the case of IR, IRS-1 phosphorylation is defective 
so is the activation of PI3K and Akt [2], therefore, GLUT4 is not 
translocated to the membrane, thus, decreasing the uptake of 
glucose into the cells. This leads to dysfunction in skeletal muscle 
with (a) IR in the muscles [28]; (b) buildup of intramuscular 
triglycerides [29,30]; (c) impaired mitochondrial function [2,31]; 
(d) impaired glycogen synthesis; and (e) lipid accumulation 
around and within the muscles [2]. Several factors cause IR, such 
as inflammation, reduced mitochondrial content or dysfunction 
mainly by accumulation of lipid intermediates in skeletal muscle 
[32]; reduced insulin signaling leading to decreased insulin-
stimulated GLUT4 translocation and aging [33].
In diabetic individuals, muscle function is compromised. 
Muscles are influenced greatly, by the levels of Myostatin, a 
protein that inhibits muscle differentiation and growth [34-37] 
and attenuates muscle fiber protein accretion [38-40]. Myostatin 
has direct metabolic effects on other tissues like adipose and liver 
as well [41]. In T2DM, there is an increase in the mRNA levels of 
Myostatin [42], and this is inversely related to insulin sensitivity 
which directly influences glucose uptake and utilization in a 
cell-specific manner [41]. Myostatin also affects glucose uptake 
indirectly, through Tumor Necrosis Factor-α (TNF-α) expression, 
which antagonizes insulin-mediated glucose uptake [43]. In 
addition, mutations in Myostatin gene and impaired Myostatin 
protein leads to increase in muscle mass in animals and humans 
[39, 44-46].
Diet plays an important role in manifestation, establishment, 
and progression of diabetes. As glucose metabolism is affected, 
it is very logical to focus on carbohydrate intake in diabetic 
patients and has been the practice for a long time. Interventions 
on regulating carbohydrate intake reduced circulating glucose 
levels. However, there is increasing evidence pointing towards 
the role of excessive intake of fats also leading to IR. T2DM 
patients show increased levels of fat uptake soon after meals 
[47]. Lipid accumulates in adipocytes within muscle tissues and 
fibers [48] which are one more factor that can cause IR [30,49]. 
In addition, chronic overload of calories with increased adiposity 
also leads to IR [50] and hypocaloric diet reduces both fat and 
lean mass [51]. IR, in the skeletal muscles, also develops when 
there is increased H2O2 production in the mitochondria as a 
result of acute and chronic intake of high-fat diet [52]. Moreover, 
high-fat diet-induced IR and glucose intolerance was decreased 
in mice that had mutated Myostatin along with decreased TNF-α 
level in muscle and adipose tissue [53]. Therefore, myostatin 
down-regulation may be beneficial to diabetic patients.
Diabetic patients also exhibit a faulty energy balance. This 
is attributed to decreased mitochondrial density, size and 
ultrastructure [54], and impairment of the oxidative capacity of 
mitochondria in the skeletal muscle [55]. The Electron Transport 
System (ETS) housed in the mitochondria, and responsible for 
producing most of the energy molecules-Adenosine Triphosphate 
(ATP), is also impaired [56]. The hydrogen molecules that 
are necessary for ATP production enter the ETS from the 
TCA cycle and β oxidation through Nicotinamide Adenine 
Dinucleotide (NAD). Higher levels of reduced Nicotinamide 
Adenine Dinucleotide (NADH) production from the Tricarboxylic 
Cycle (TCA) and β oxidation are reported from muscle cells of 
T2DM patients [57]. This results in a buildup of high reducing 
equivalents in energy metabolism, leading to the accumulation of 
acetyl-CoA, ceramides, and diacylglycerols which correlate with 
IR and altered insulin cascades [58].
Oxidative stress is one more factor that may play a role in 
the development of diabetes [59,60]. Oxidative stress increases 
with aging [61] and a combination of low intake of antioxidants 
with decreased PA contributed to the escalation of oxidative 
stress [52,62]. One of the molecules that contribute to oxidative 
stress is nitric oxide (NO). Many metabolic reactions in the 
body are mediated by NO, which is produced with the help of 
the enzyme Nitric Oxide Synthase (NOS). NOS are produced 
in several different organs of the body including pancreatic β 
cells [63]. In T1DM, β cell degradation is associated with NOS, 
which is associated with increased pro-inflammatory cytokines 
that induce apoptosis of cells [64]. However, dual effects of 
NO have been reported. Depending on the NO concentration, 
anti-apoptotic or pro-apoptotic effects may occur [65]. At high 
concentrations, excessive NO is detrimental to the β cells and at 
low concentrations NO protects these cells. It is also important 
to note that under IR and T2DM conditions, there is increased 
circulation of NOS inhibitor in the plasma which results in 
decreased NO production – a natural adaptation of the body to 
reduce NO production. On the other hand, when there is impaired 
glucose-stimulated insulin secretion (GSIS), NO production is 
enhanced [66]. Therefore, normal functioning of the GSIS is 
necessary, to avoid the deleterious effects of NO. Moreover, 
insulin can also increase NOS activity [67]. 
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During the last decade, the importance of microRNA (miRNA) 
in the regulation of metabolism had been brought to light. 
miRNA are small molecules that play an important role in the 
eventual expression and translation of mRNA and proteins. They 
have been implicated in glucose homeostasis and IR as well. 
Interestingly, miRNAs’ are associated with changes in fat mass 
and IR in children [68]. Silencing certain miRNA’s like miR103 and 
miR107 improved glucose homeostasis and insulin sensitivity 
while other miRNA’s like miR103 and miR107 impaired glucose 
homeostasis [69]. Glucose tolerance and IR is also modulated by 
Let-7. Overexpression of Let-7 led to IR [70] and has been found 
at higher levels in T2DM patients [71]. miRNA’s such as miR133a 
and miR206 were downregulated in T2DM patients and an 
inverse relationship between IR and miR133a exists [72].
Recently, Osteocalcin (OC), a protein secreted by bone cells 
and important for bone formation has been shown to play an 
endocrine role in influencing insulin secretion and sensitivity. 
Undercarboxylated OC (UnOC) fraction increased insulin 
secretion and sensitivity and decreased visceral fat in males and 
females [73]. Increase in serum OC and UnOC levels, improved 
insulin secretion and/or sensitivity in humans [74,75]. Lack of 
OC led to glucose intolerance in muscles [76]. Mice, genetically 
modified to increase UnOC are protected from T2DM and obesity 
[76]. Injection of OC improved glucose tolerance and insulin 
sensitivity in high fat fed mice [76]. Mice treated with intermittent 
OC injections displayed more mitochondria in their skeletal 
muscles and increased energy utilization. In addition, they were 
protected from diet-induced obesity, improved glucose handling, 
prevented the development of T2DM, and liver steatosis [76]. 
Interestingly, mice lacking OC have decreased β cell proliferation 
[75]. Therefore, OC may be used as treatment option along with 
medications, diet modifications, and PA interventions.
Physical activity/ Exercise
Global industrialization is responsible for drastic lifestyle 
changes in humans. One major drawback is the lack and/or 
reduction of PA, which is essential for maintaining health and 
healthy aging. Lack of sufficient daily PA is an underappreciated 
primary cause of most chronic conditions [77]. Therefore, there 
is increasing emphasis on maintaining PA and EX regimen 
throughout an individual’s lifetime. PA/EX during childhood 
influences many organ systems in the body to function and develop 
normally, in addition to reducing obesity and complications 
that arise from diabetes. In adults, also PA/ EX is encouraged to 
reduce the risk of developing several health issues that may arise, 
during and after middle age. The elderly are more susceptible to 
frailty, and a daily EX regimen is emphasized to maintain better 
health, thereby, improving the quality of their life [78]. There 
are reports of age-related decreases in muscle mass, and EX 
regimen increased muscle mass and strength as one age [79]. 
Convincing evidence suggests that sedentary lifestyle increased 
the risk of cardiovascular disease (CVD) in T1DM patients 
[80]. In addition, inactive muscles are not capable of removing 
oxidative intermediates due to insufficient electron transport 
and results in lipid toxicity [81,82]. Moreover, continued long-
term reductions in PA/EX and inactivity are the primary causes 
of IR [52,83]. Daily PA reversed the risk of development of 
diabetes in prediabetic patients [52]. Furthermore, muscle loss 
occurs with aging and there is a decline in aerobic capacity with 
a dramatic decrease in PA/EX [51,84]. A Normal function of an 
individual is dependent on sufficient aerobic capacity and muscle 
strength [51]. Therefore, an increase daily PA and a continuous 
EX regimen are important to avoid several medical complications 
including diabetes.
There are several benefits of EX-(a) decreased mortality 
up to 40%and lower utilization of health care services [85-94]; 
(b) prevention of Coronary Heart Disease (CHD) [95,96]; (c) 
decreased lipid levels [97,98]; and (d) body composition [99]. 
With regular EX, primary and secondary prevention of several 
chronic conditions including diabetes has been reported [51]. 
Regular EX also decreased glucose levels and increased insulin 
receptors effectiveness [100].
EX can be of different types-aerobic EX-involves a large group 
of muscles. This EX regimen is for extended periods of time 
and includes multiple repetitions. It also includes endurance 
EX for both the muscles and heart and is reported to increase 
mitochondrial abundance and aerobic capacity [101]. On the other 
hand, resistance EX (REX) involves a movement of high loads 
using machines or weights or both and the number of repetitions 
is relatively less [102,103]. This is reported to increase muscle 
mass in middle-aged and elderly [101]. Both aerobic EX and REX 
are associated with decreased risk of T2DM. Even a single bout of 
muscle contraction increased insulin sensitivity in animals and 
humans [104-113]. 
Another important fact is that EX can also induce non-insulin 
dependent uptake of glucose. For example, IR patients show 
contraction mediated uptake of glucose through calcium and 
adenosine monophosphate-activated protein kinase (AMPK) 
[114,115] with an increase in AMPK α 2 mediated glucose uptake 
after EX [116]. The intensity of EX controls the uptake of glucose 
and sometimes both pathways may be involved in this. Whole 
body strength training for 16 weeks shows improved homeostatic 
model assessment-IR (HOMA-IR) in T2DM Hispanic adults [117] 
and increased hepatic insulin sensitivity [28]. 
EX influences NOS, a membrane protein found in the muscle 
fibers, and is increased in many disease conditions [118,119]. 
There are three kinds of NOS-eNOS which is co-localized 
with mitochondrial markers in muscle fibers [118]; iNOS that 
increased under conditions of inflammation and the presence of 
pro-inflammatory cytokines [120,121]; and nNOS that is found 
in the outer membrane of muscle fibers and neuromuscular 
junctions [119]. During EX, NO production is increased initially 
due to a burst of the NOS activity [122]. NO production is induced 
by an increase in pro-inflammatory cytokines due to EX, which 
supplies oxygen during vigorous EX [123]. Prolonged treadmill 
EX, also increased protein expression of nNOS and eNOS and the 
contractile activity of skeletal muscles [122,124,125].
EX is also influenced by miRNA’s as they control muscle 
proliferation, differentiation and apoptosis [126] and regulate 
the aging process and changes in skeletal muscles [127-129]. 
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During aging, in mice, the quadriceps muscles expressed 
upregulated miR7, miR206; miR468, miR542, and miR698 while 
miR124a, miR181a, miR221, miR382, miR434, miR455 were 
downregulated [130]. In Rhesus monkeys, miR15a, miR18a, 
miR144, and miR451 were up-regulated and miR181a/b was 
downregulated with aging [131]. Both aerobic EX and REX 
influenced the expression of different miRNAs. During aerobic 
EX miR181, miR1 and miR107 are up-regulated and miR23 is 
downregulated in mice [132]. But in humans, miR1 and miR133 
increased before EX, rather than after EX [133] in several muscles. 
REX down regulated muscle specific miR-1 and miR133a, in mice 
[134]. In humans, miRNA up-regulation and downregulation was 
reported based on responders with reference to hypertrophy 
of vastus lateralis muscles [135]. Downregulation of miR26a, 
miR29a and miR378 was reported in low responders with 
upregulation of miR451. There were 15 other miRNAs’ that were 
not affected by REX. These miRNA’s may modulate yet another 
pathway-the mammalian target of rapamycin (mTOR) signaling 
pathway, which is activated during muscle protein anabolism 
and REX [135]. REX also increased insulin-like growth factor-I 
(IGF-I) and decreased miR1 which may result in increased muscle 
cross-sectional area, in elderly men and women after EX [136]. 
In addition, EX also increased UnOC this had potentially positive 
effects on glucose tolerance [73].
Impact of exercise on diabetes
T1DM: In T1DM individuals, aerobic EX maintained glycemic 
control and decreased the amount of insulin required to maintain 
circulating glucose levels, although HbA1cdid not change [17]. 
After EX, insulin in pancreatic β cells increased and insulin 
secretion by the pancreas also enhanced. It also stimulated the 
uptake of glucose by muscles and supported muscle contraction. 
In addition, muscle cells were protected from oxidative damage 
[137-142]. Short term and long term aerobic EX also increased 
GLUT4 [142,143] which is required for glucose transport into the 
cells.
NOS is highly influenced by EX. Interestingly, although 
GLUT4 mediated transport of glucose is independent of NO, NOS 
activity enhanced glucose transport and the NOS inhibitor-L-
NG-Monomethyl Arginine (L-NMMA) attenuated glucose uptake 
[124]. At low concentrations, NOS can positively influence insulin 
secretions while at high concentrations it may have a negative 
influence on pancreatic β cells and inhibit insulin secretion 
[63]. Therefore, TIDM patients may have to increase the intake 
of the diet containing anti-oxidants, before EX, to counter the 
production of NO.
EX is an indispensable component of treatment for patients 
with T1DM [144]. Even low-intensity EX helps [17] and Stretching 
EX decreased T1DM neuropathy and pain [145]. However, it has 
been reported that moderate EX helped in declining glucose 
levels rapidly during the exercise and slowly reversed back after 
the exercise when compared to high-intensity EX and REX [146]. 
High-intensity EX programs showed great improvements in 
insulin response to oral glucose load compared to lower intensity 
aerobic EX [147]. Therefore, the overall impact on circulating 
glucose levels were attained more with intermittent moderate 
EX and some high-intensity EX.
T2DM: In insulin resistant middle-aged men, aerobic EX 
decreased muscle and plasma myostatin and this strongly 
correlated with insulin sensitivity and diabetic patients [148]. In 
mice, there was decreased the circulation of myostatin, insulin 
and glucose levels [148] after EX, which decreased IR. Aerobic 
training increased insulin sensitivity in T2DM patients [149,150]. 
In addition, aerobic EX in T2DM patients reversed advanced 
glycation in kidney and ameliorated the early signs of diabetic 
nephropathy [151]. Kidney function is also influenced by EX. There 
are reports that there is reduced glomerular mesangial volume 
and decreased albumin excretion, a level of lipid peroxidation 
and fibrogenesis in glomerular mesangium [152-154]. Moreover, 
improved cardiac function may also protect kidney function after 
EX [155]. Aerobic EX showed increased glucose disposal rate in 
these patients [156]. In addition, treadmill EX in rats increased 
insulin sensitivity, improved insulin-mediated capillary 
recruitment in combination with augmented muscle glucose 
uptake [137].
Endurance training in T2DM individuals increased the 
expression of GLUT4 protein and mRNA [157,158]. EX also 
decreased glucose-stimulated insulin levels [159] and myostatin 
[41]; especially high bouts of Endurance EX decreased myostatin 
mRNA levels [160,161]. Furthermore, myostatin null mice 
displayed decreased endurance performance and energy is 
regulated by increased mitochondrial enzymes such as citric 
synthase and succinate dehydrogenase [162,163]. An important 
fact is that levels of myostatin mRNA is different depending on 
the time after EX [164]. Another way REX can influence muscle 
maybe by decreasing skeletal muscle myostatin mRNA expression 
and plasma protein levels [165-170]. However, some reports on 
REX did not show the same benefits [171,172] and this may be 
due to differences in the experimental protocols such as - terms 
of rest, repetition, a number of contractions, intensity, training 
state and biopsy sampling time. 
Many benefits of REX have been reported in T2DM patients. 
In addition, to decreasing neuropathy and pain, REX improved 
the glycemic index, HbA1C, adiposity and muscle strength 
[145,173,174], it also reduced fasting insulin, increased insulin 
sensitivity, glucose disposal rates and improved glucose 
tolerance [175-179]. REX increased glucose uptake in muscles 
by increasing and translocating GLUT4 to the plasma membrane 
[180]. In addition, REX also increased skeletal muscle cross-
sectional area, muscle cell mitochondria [181] and improved 
mitochondrial function [182-184].
Risks and barriers of EX: Many patients have reported 
several difficulties in fulfilling the EX regimens recommended to 
them. Some of the problems they face may include allocation of 
time; work schedule, weather, proximity and access to facilities, 
lack of motivation [185]. Among those who have low economic 
status, several psychological factors, like embarrassment and 
fear of failure, negative body image and chronic disease stigma 
that needs vigilance during PA/EX (especially among T1DM 
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patients with fear of hypoglycemia) [186] are also barriers that 
contribute to non-compliance. Other obstacles include numerous 
intrapersonal reasons like lack of energy, lack of time due to 
other leisure activities and perceived competencies, as well 
as interpersonal reasons such as family, friend peer support, 
environmental/organizational factors, opportunity, resources, 
etc. [77,187-189]. 
Although PA/EX is recommended for healthy living, it is 
associated with several risks as well. Usually high intensity, as 
well as rapid increase in intensity is detrimental for the patients. 
One very dangerous side-effect is the late onset of hypoglycemia 
after EX, especially in T1DM individuals. Aerobic EX caused acute 
risk of hypoglycemia [190], while intermittent and REX had the 
lowest likelihood of hypoglycemia [185,191]. Another important 
physiological change is that moderate and exhaustive EX may 
generate oxidative stress, which can enhance IR [192]. Therefore, 
when interventional methods are recommended, a combination 
of several factors such as intensity of EX and co-morbidities 
including CVD, stroke, etc. should be taken into consideration.
Summary
In order to successfully reduce the risks of diabetes in humans 
and maintain a healthy life with diabetes, significant multiple 
lifestyle changes seems to be the best approach [193-199]. These 
changes include diet modifications and PA/EX with medicines 
[200,201]. Consumption of decreased carbohydrates and fats, 
with the inclusion of moderate to high amounts of fiber, will be 
the major dietary changes for prediabetic and diabetic patients.
Diet adjustments should accompany changes in PA/EX as 
well. Both T1DM and T2DM will benefit from these changes. 
Although T1DM patients may have to continue taking insulin, 
the amount of insulin can be reduced significantly. Regular 
EX is important as it reduced HbA1C in T1DM [185], however, 
moderate caloric restriction intake with PA reduced fat mass 
[202] can be beneficial too.
T2DM patients may benefit more extensively with diet 
and lifestyle changes. Non-diabetic children of T2DM and IR 
T2DM patients showed decreased insulin sensitivity, muscle 
mitochondrial density, mitochondrial electron transport and 
insulin-mediated skeletal muscle glucose uptake [22,23,56,203], 
putting them at high risk of developing diabetes. Such individuals 
can delay the onset of diabetes by increasing their PA/ EX. 
Independent of the type of EX, both prediabetic and diabetic 
patients showed benefits with increased PA by improving insulin 
sensitivity and maintaining glucose homeostasis. Moreover, the 
habitual physical activity may prevent and postpone non-insulin 
dependent diabetes [100]. Aerobic EX is good, so is repetitive 
EX [204]. The overall an increase in PA, increased post-receptor 
insulin signaling increase in GLUT4 mRNA and protein levels 
[63,157], glucose synthase [205], hexokinase [206], β cell 
function [146], An influx of glucose to muscles, enhanced muscle 
capillarization and blood flow [207,208]. Increased blood flow, 
stimulated NO which induced smooth muscle relaxation and 
vasodilation [209]. However, REX may be better than aerobic 
EX, and may result in program retention and success of the 
interventional objectives [185]. 
As mentioned earlier, EX can affect several pathways to 
maintain glucose homeostasis. Apart from increasing insulin 
sensitivity and mobilizing glucose into the cells, it can influence 
the insulin signaling pathway through miRNAs’ to stimulate 
glucose uptake. Another protein that is impacted due to EX is OC, 
which increased insulin secretion, sensitivity, and mitochondria 
in the muscles, thereby, affecting the energy balance which is 
disrupted in diabetes [75]. 
Conclusion
In conclusion, it is established that people with moderate 
to high levels of EX have lower mortality rate and utilization of 
health care services. However, physical fitness is dependent on 
nutritional status, dietary and smoking, genetics, socio-economic 
factors and PA. In addition, it also depends on pulmonary and 
muscle function health status of other organ systems, medications, 
and orthopedic limitations [77,210]. To have attainable goals, 
which may be more pleasant and an inspiring experience [211], 
graduated physical activity with small increments and long term 
goals on the health is recommended [61]. Therefore, progressive 
resistant therapy (PRT) is safe and an effective EX regimen, 
which [212] promotes favorable energy balance and decreased 
visceral fat deposition with an increase in basal metabolism 
and activity will be more beneficial. It also improved insulin 
sensitivity and glycemic control. More importantly, it is safe for 
frail elderly individuals and patients with co-morbidities like 
CVD and obesity. Moreover, PRT increased glucose disposal 
rates, glycogen storage capacity, GLUT4 receptors in skeletal 
muscle and insulin sensitivity [212]. However, it is important to 
have good glycemic control for EX to benefit [17].
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